Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden
Ernani Luis
EL
Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, USA.
Morgentaler
Abraham
A
D017677:Age Distribution; D002318:Cardiovascular Diseases / Q000209:etiology; D016903:Drug Monitoring / Q000379:methods; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D011086:Polycythemia / Q000139:chemically induced; D017430:Prostate-Specific Antigen / Q000097:blood; D011469:Prostatic Diseases / Q000139:chemically induced; D012307:Risk Factors; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000172:deficiency / Q000627:therapeutic use*
D008055:Lipids; D013739:Testosterone; D017430:Prostate-Specific Antigen